HemaCare Corporation

Equities

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

2020	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
2020	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

HemaCare Corporation Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2017

August 21, 2017 at 08:00 am EDT

HemaCare Corp. reported unaudited earnings results for the first six months ended June 30, 2017. For the period, revenue was $8,657,000 compared to $5,779,000 a year ago. Income from continuing operations before income taxes was $574,000 compared to loss of $73,000 a year ago. Net income was $552,000 compared to net loss of $79,000 a year ago.

Latest news about HemaCare Corporation

HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	20-06-02	CI
MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	20-01-21	CI
Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	20-01-02	CI
Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	19-12-15	CI
HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	19-11-19	CI
HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	19-08-27	CI
Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-20	CI
HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	19-03-26	CI
HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	18-12-19	CI
HemaCare Corporation Moves its Global Headquarters to Northridge, California	18-12-06	CI
HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	18-11-14	CI
HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	18-08-21	CI
HemaCare Corporation Announces Executive Appointments	18-07-17	CI
HemaCare Corporation Reports Earnings Results for the Full Year Ended December 31, 2017	18-03-08	CI
HemaCare Corporation and Charles River Laboratories International Inc. Announces Strategic Partnership to Accelerate Drug Discovery and Development	18-02-06	CI
HemaCare Corporation Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2017	17-08-21	CI
HemaCare Signs Long Term Lease for Facility Relocation and Expansion	17-07-24	CI
HemaCare Corporation Reports Financial Results for the Year Ended December 31, 2016	17-03-13	CI
HemaCare Corporation Signs Distribution Agreement with Almog Diagnostic	17-02-20	CI
HemaCare Corporation announced that it expects to receive $5 million in funding from OBF Investments LLP	17-01-05	CI
HemaCare Signs Distribution Agreement with Accuresearch Korea, Inc	16-10-31	CI
HemaCare Corp. Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2016	16-09-06	CI
HemaCare Corporation Signs Strategic Distribution Agreement with MT-Biological Science and Technology Co. Ltd	16-05-12	CI
HemaCare Corp. Expands its Offering of Stem Cell-Enriched Peripheral Blood	16-03-28	CI
HemaCare to Increase Bone Marrow Capability	16-03-21	CI

Chart HemaCare Corporation

Duration

Period

More charts

Company Profile

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HEMACARE CORPORATION	+0.24%	346M
HCA HEALTHCARE, INC.	+14.10%	81.84B
CVS HEALTH CORPORATION	-30.15%	70.69B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.03B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.90%	16.97B
FRESENIUS SE & CO. KGAA	-0.36%	16.83B
QUEST DIAGNOSTICS INCORPORATED	-1.12%	15.28B
FRESENIUS MEDICAL CARE AG	+5.90%	12.41B
DAVITA INC.	+35.78%	12.26B
EUROFINS SCIENTIFIC SE	-4.20%	11.86B

Other Healthcare Facilities & Services